scholarly journals Targeted molecular therapy (modified RIST regimen) in relapsed high risk stage IV neuroblastoma: two cases report

2018 ◽  
Vol 2 (1) ◽  
Author(s):  
Paolo Indolfi ◽  
Selim Corbacioglu ◽  
Silverio Perrotta ◽  
Francesca Rossi ◽  
Antonio Marte ◽  
...  
Keyword(s):  
High Risk ◽  
Stage Iv ◽  
Molecular Therapy ◽  
Targeted Molecular Therapy ◽  
Stage Iv Neuroblastoma

Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children’s Cancer Group Study

2000 ◽  
Vol 18 (24) ◽  
pp. 4067-4076 ◽  
Author(s):  
Robert C. Seeger ◽  
C. Patrick Reynolds ◽  
Richard Gallego ◽  
Daniel O. Stram ◽  
Robert B. Gerbing ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Induction Chemotherapy ◽  
Neuroblastoma Cells ◽  
Stage Iv ◽  
Prognostic Impact ◽  
Cancer Group ◽  
Stage Iv Neuroblastoma

PURPOSE: This study investigated the prognostic value of quantifying tumor cells in bone marrow and blood by immunocytology in children with high-risk, metastatic neuroblastoma. PATIENTS AND METHODS: Patients with stage IV neuroblastoma (N = 466) registered on Children’s Cancer Group study 3891 received five cycles of induction chemotherapy and were randomized either to myeloablative chemoradiotherapy with autologous purged bone marrow rescue or to nonmyeloablative chemotherapy. Subsequently, they were randomized to 13-cis-retinoic acid or no further treatment. Immunocytologic analyses of bone marrow and blood were performed at diagnosis, week 4, week 12, bone marrow collection, and end induction and were correlated with tumor biology, clinical variables, treatment regimen, and event-free survival (EFS). RESULTS: Immunocytology identified neuroblastoma cells in bone marrow of 81% at diagnosis, 55% at 4 weeks, 27% at 12 weeks, 19% at bone marrow collection, and 14% at end induction. Tumor cells were detected in blood of 58% at diagnosis and 5% at collection. There was an adverse effect on EFS of increasing tumor cell concentration in bone marrow at diagnosis (P = .04), at 12 weeks (P = .006), at bone marrow collection (P < .001), and at end induction (P = .07). Positive blood immunocytology at diagnosis was associated with decreased EFS (P = .003). The prognostic impact of immunocytology was independent of morphologically detected bone marrow disease, MYCN status, and serum ferritin level in bivariate Cox analyses. CONCLUSION: Immunocytologic quantification of neuroblastoma cells in bone marrow and blood at diagnosis and in bone marrow during induction chemotherapy provides prognostic information that can identify patients with very high-risk disease who should be considered for experimental therapy that might improve outcome.

Is complete resection of high-risk stage IV neuroblastoma associated with better survival?

2015 ◽  
Vol 50 (12) ◽  
pp. 2107-2111 ◽  
Author(s):  
Fanny Yeung ◽  
Patrick Ho Yu Chung ◽  
Paul Kwong Hang Tam ◽  
Kenneth Kak Yuen Wong
Keyword(s):  
High Risk ◽  
Stage Iv ◽  
Complete Resection ◽  
Stage Iv Neuroblastoma

Treatment of Pulmonary Metastases in Children With Stage IV Nephroblastoma With Risk-Based Use of Pulmonary Radiotherapy

2012 ◽  
Vol 30 (28) ◽  
pp. 3533-3539 ◽  
Author(s):  
Arnauld Verschuur ◽  
Harm Van Tinteren ◽  
Norbert Graf ◽  
Christophe Bergeron ◽  
Bengt Sandstedt ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
High Risk ◽  
Pulmonary Metastases ◽  
Stage Iv ◽  
Line Treatment ◽  
Event Free Survival ◽  
First Line ◽  
Free Survival ◽  
First Line Treatment

Purpose The purpose of this study was to determine the outcome of children with nephroblastoma and pulmonary metastases (PM) treated according to International Society of Pediatric Oncology (SIOP) 93-01 recommendations using pulmonary radiotherapy (RT) in selected patients. Patients and Methods Patients (6 months to 18 years) were treated with preoperative chemotherapy consisting of 6 weeks of vincristine, dactinomycin, and epirubicin or doxorubicin. If pulmonary complete remission (CR) was not obtained, metastasectomy was considered. Patients in CR received three-drug postoperative chemotherapy, whereas patients not in CR were switched to a high-risk (HR) regimen with an assessment at week 11. If CR was not obtained, pulmonary RT was mandatory. Results Two hundred thirty-four of 1,770 patients had PM. Patients with PM were older (P < .001) and had larger tumor volumes compared with nonmetastatic patients (P < .001). Eighty-four percent of patients were in CR postoperatively, with 17% requiring metastasectomy. Thirty-five patients (16%) had multiple inoperable PM and required the HR protocol. Only 14% of patients received pulmonary RT during first-line treatment. For patients with PM, 5-year event-free survival rate was 73% (95% CI, 68% to 79%), and 5-year overall survival (OS) rate was 82% (95% CI, 77% to 88%). Five-year OS was similar for patients with local stage I and II disease (92% and 90%, respectively) but lower for patients with local stage III disease (68%; P < .001). Patients in CR after chemotherapy only and patients in CR after chemotherapy and metastasectomy had a better outcome than patients with multiple unresectable PM (5-year OS, 88%, 92%, and 48%, respectively; P < .001). Conclusion Following the SIOP protocol, pulmonary RT can be omitted for a majority of patients with PM and results in a relatively good outcome.

scholarly journals Malnutrition Risk at Solid Tumor Diagnosis: the Malnutrition Screening Tool in a Large US Cancer Institute

2021 ◽  
Author(s):  
Kunal C. Kadakia ◽  
James T. Symanowski ◽  
Aynur Aktas ◽  
Michele L. Szafranski ◽  
Jonathan C. Salo ◽  
...  
Keyword(s):  
High Risk ◽  
Solid Tumor ◽  
Screening Tool ◽  
Stage Iv ◽  
Cancer Site ◽  
Black Race ◽  
Symptom Scores ◽  
Stage Iv Disease ◽  
Multivariable Regression ◽  
Low Bmi

Abstract BackgroundIn cancer, malnutrition (MN) is common and negatively impacts tolerance and outcomes of anti-tumor therapies. The aim of this study was to evaluate the prevalence of MN risk and compare the clinicodemographic features between those with high Malnutrition Screening Tool (MST) scores (i.e., ≥2 of 5 = high risk for MN, H-MST) to low scores (L-MST). MethodsA cohort of 3,585 patients (May 2017 through December 2018), who completed the MST at least once at the time of diagnosis of any stage solid tumor were analyzed. Logistic regression tested for associations betweenclinicodemographic factors, symptom scores, and H-MST prevalence. ResultsThe median age was 64 years (25-75 IQR, 55-72), with 62% females and 81% White. Most common tumor primary sites were breast (28%), gastrointestinal (GI) (21%), and thoracic (13%). Most had non-metastatic disease (80%). H-MST was found in 28% - most commonly in upper (58%) and lower GI (42%), and thoracic (42%) tumors. L-MST was most common in breast (90%). Multivariable regression confirmed that Black race (OR 1.9, 95% CI 1.5-2.4, p=<0.001), cancer primary site (OR 1.6-5.7, p=<0.001), stage IV disease (OR 1.8, 95% CI 1.4-2.2, p=<0.001), low BMI (OR 4.2, 95% CI 2.5-6.9 p=<0.001), and higher symptom scores were all independently associated with H-MST. ConclusionsNearly one-third of solid tumor oncology patients at diagnosis were at high risk of MN. Patients with breast cancer rarely had MN risk at diagnosis. Significant variation was found in MN risk by cancer site, stage, race, and presence of depression, distress, fatigue, and trouble eating/swallowing.

Targeted molecular therapy of malignant gliomas

2005 ◽  
Vol 5 (3) ◽  
pp. 186-197 ◽  
Author(s):  
Santosh Kesari ◽  
Naren Ramakrishna ◽  
Claire Sauvageot ◽  
Charles D. Stiles ◽  
Patrick Y. Wen
Keyword(s):  
Malignant Gliomas ◽  
Molecular Therapy ◽  
Targeted Molecular Therapy
Sign in / Sign up

Export Citation Format

Share Document